Is sleep disruption a causal driver of neurodegeneration or merely a downstream marker, and can sleep/circadian restoration slow disease progression?
Background
Sleep disturbances are nearly universal in neurodegenerative diseases, affecting 40-90% of patients with AD, PD, and other disorders. Key questions remain:
...
Experiment: Sleep and Circadian Dysfunction in Neurodegeneration
Rank: 112
Key Question
Mermaid diagram (expand to render)
Is sleep disruption a causal driver of neurodegeneration or merely a downstream marker, and can sleep/circadian restoration slow disease progression?
Background
Sleep disturbances are nearly universal in neurodegenerative diseases, affecting 40-90% of patients with AD, PD, and other disorders. Key questions remain:
Does sleep disruption cause neurodegeneration or result from it?
What is the temporal relationship - does poor sleep predict faster decline?
Can therapeutic sleep optimization modify disease trajectory?
Hypotheses
H1: Chronic sleep fragmentation causally contributes to protein aggregation (impaired glymphatic clearance)
H2: Circadian disruption accelerates tau phosphorylation and propagation
H3: Sleep optimization (pharmacological or behavioral) will reduce neurodegeneration biomarkers
H4: Sleep phenotypes define distinct disease subtypes with different progression rates
Validation Protocol
Study Design: Sleep-Circadian-Neurodegeneration (SCAN) Study
Cohort Structure:
| Group | N | Criteria | |-------|---|----------| | Subjective cognitive decline with sleep complaints | 100 | Poor sleep, no objective impairment | | MCI with sleep disorder | 75 | MCI + PSG-confirmed disorder | | Early AD/PD | 100 | Mild disease + sleep complaints | | Age-matched good sleep controls | 75 | Normal sleep, no neurodegenerative signs |
Assessments (annual for 4 years):
Sleep measures:
Polysomnography (PSG) - full, at baseline and 2 years
Actigraphy (14 days quarterly)
Sleep diaries
Epworth Sleepiness Scale, PSQI
2. Neurodegeneration biomarkers:
CSF: Aβ42/40, p-tau181, total tau, α-syn SAA, NfL
Plasma: NfL, p-tau217, GFAP
Amyloid PET (Florbetaben)
Tau PET (MK-6240) in AD cohort
Dopaminergic PET (FP-CIT) in PD cohort
3. Cognitive/motor:
AD: MoCA, RBANS, Clinical Dementia Rating
PD: MDS-UPDRS, Hoehn & Yahr
Key Endpoints
Primary: Change in neurodegeneration biomarkers per unit of sleep disruption
Secondary: Does sleep improvement correlate with biomarker stabilization?
Tertiary: Define sleep-phenotype subtypes within each disease
Model Systems
Animal Models
Sleep deprivation in 5xFAD mice (amyloid model)
Sleep fragmentation in P301S tau mice
Circadian disruption in MPTP/6-OHDA PD model
In Vitro
Glymphatic clearance assays under sleep-deprived conditions
Circadian clock gene knockdown in neuronal cultures
Expected Outcomes
Causality determination: Establish whether sleep is causal vs. correlative
Mechanistic insight: Map sleep → protein clearance pathway dysfunction